Swiss National Bank lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 4.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 923,000 shares of the company’s stock after selling 43,800 shares during the quarter. Swiss National Bank owned about 0.24% of Moderna worth $38,378,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB grew its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc purchased a new stake in shares of Moderna during the 4th quarter worth about $37,000. Larson Financial Group LLC grew its holdings in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.
Moderna Price Performance
Shares of MRNA opened at $34.62 on Monday. The business’s fifty day moving average price is $35.94 and its 200 day moving average price is $47.15. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The stock has a market capitalization of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on Moderna
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
- Five stocks we like better than Moderna
- What Investors Need to Know to Beat the Market
- How to Build the Ultimate Everything ETF Portfolio
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the S&P/TSX Index?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.